These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 35742818)

  • 1. Trastuzumab and Doxorubicin Sequential Administration Increases Oxidative Stress and Phosphorylation of Connexin 43 on Ser368.
    Pecoraro M; Marzocco S; Franceschelli S; Popolo A
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trastuzumab-induced cardiotoxicity and role of mitochondrial connexin43 in the adaptive response.
    Pecoraro M; Pinto A; Popolo A
    Toxicol In Vitro; 2020 Sep; 67():104926. PubMed ID: 32599261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simvastatin Reduces Doxorubicin-Induced Cardiotoxicity: Effects beyond Its Antioxidant Activity.
    Pecoraro M; Marzocco S; Belvedere R; Petrella A; Franceschelli S; Popolo A
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An update of the molecular mechanisms underlying doxorubicin plus trastuzumab induced cardiotoxicity.
    Anjos M; Fontes-Oliveira M; Costa VM; Santos M; Ferreira R
    Life Sci; 2021 Sep; 280():119760. PubMed ID: 34166713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies.
    Rayson D; Richel D; Chia S; Jackisch C; van der Vegt S; Suter T
    Ann Oncol; 2008 Sep; 19(9):1530-9. PubMed ID: 18480068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
    Yu AF; Singh JC; Wang R; Liu JE; Eaton A; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
    Oncologist; 2017 Jun; 22(6):642-647. PubMed ID: 28341761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.
    Miller K; Cortes J; Hurvitz SA; Krop IE; Tripathy D; Verma S; Riahi K; Reynolds JG; Wickham TJ; Molnar I; Yardley DA
    BMC Cancer; 2016 Jun; 16():352. PubMed ID: 27259714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cumulative incidence of chemotherapy-induced cardiotoxicity during a 2-year follow-up period in breast cancer patients.
    Cho H; Lee S; Sim SH; Park IH; Lee KS; Kwak MH; Kim HJ
    Breast Cancer Res Treat; 2020 Jul; 182(2):333-343. PubMed ID: 32468335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
    Slamon DJ; Leyland-Jones B; Shak S; Fuchs H; Paton V; Bajamonde A; Fleming T; Eiermann W; Wolter J; Pegram M; Baselga J; Norton L
    N Engl J Med; 2001 Mar; 344(11):783-92. PubMed ID: 11248153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal Changes in Multiple Biomarkers Are Associated with Cardiotoxicity in Breast Cancer Patients Treated with Doxorubicin, Taxanes, and Trastuzumab.
    Putt M; Hahn VS; Januzzi JL; Sawaya H; Sebag IA; Plana JC; Picard MH; Carver JR; Halpern EF; Kuter I; Passeri J; Cohen V; Banchs J; Martin RP; Gerszten RE; Scherrer-Crosbie M; Ky B
    Clin Chem; 2015 Sep; 61(9):1164-72. PubMed ID: 26220066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic Evidence of MSCs-Derived Exosomes in Doxorubicin/Trastuzumab-Induced Cardiotoxicity: Beyond Mechanistic Target of NRG-1/Erb Signaling Pathway.
    Ebrahim N; Al Saihati HA; Mostafa O; Hassouna A; Abdulsamea S; Abd El Aziz M El Gebaly E; Abo-Rayah NH; Sabry D; El-Sherbiny M; Madboly AG; Hussien NI; Saadani REH; Ebrahim HA; Badr OAM; Elsherbiny NM; Salim RF
    Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type IIB DNA topoisomerase is downregulated by trastuzumab and doxorubicin to synergize cardiotoxicity.
    Jiang J; Mohan N; Endo Y; Shen Y; Wu WJ
    Oncotarget; 2018 Jan; 9(5):6095-6108. PubMed ID: 29464058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab cardiotoxicity in HER2-positive breast cancer patients in tertiary health care center, sultanate of Oman.
    Alghafar DA; Younos I; Baimani KA; Al-Salhi D; Al-Riyami A; Rizvi S; Buckley NE
    J Oncol Pharm Pract; 2021 Mar; 27(2):312-321. PubMed ID: 32340535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Familial breast cancer, pregnancy and cardiotoxicity associated with the use of doxorubicin and reaction with trastuzumab.
    Valente PMS; Gomes MCB; Martins WA; Castilho SR
    J Oncol Pharm Pract; 2022 Dec; 28(8):1893-1897. PubMed ID: 35321591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study.
    Jacquinot Q; Meneveau N; Chatot M; Bonnetain F; Degano B; Bouhaddi M; Dumoulin G; Vernerey D; Pivot X; Mougin F
    BMC Cancer; 2017 Jun; 17(1):425. PubMed ID: 28629338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiotoxic Effects of Short-Term Doxorubicin Administration: Involvement of Connexin 43 in Calcium Impairment.
    Pecoraro M; Rodríguez-Sinovas A; Marzocco S; Ciccarelli M; Iaccarino G; Pinto A; Popolo A
    Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29019935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
    Tan-Chiu E; Yothers G; Romond E; Geyer CE; Ewer M; Keefe D; Shannon RP; Swain SM; Brown A; Fehrenbacher L; Vogel VG; Seay TE; Rastogi P; Mamounas EP; Wolmark N; Bryant J
    J Clin Oncol; 2005 Nov; 23(31):7811-9. PubMed ID: 16258083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical management of drug-induced cardiotoxicity in patients with HER-2+ breast cancer: current recommendations and future outlook.
    Chianca M; L'Abbate S; Fabiani I; Aimo A; Emdin M; Passino C; Fedele A; Cipolla CM; Cardinale DM
    Expert Opin Drug Metab Toxicol; 2023 Feb; 19(2):109-119. PubMed ID: 36989398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab cardiotoxicity: from clinical trials to experimental studies.
    Nemeth BT; Varga ZV; Wu WJ; Pacher P
    Br J Pharmacol; 2017 Nov; 174(21):3727-3748. PubMed ID: 27714776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast cancer drug trastuzumab induces cardiac toxicity: evaluation of human epidermal growth factor receptor 2 as a potential diagnostic and prognostic marker.
    Johnson TA; Singla DK
    Can J Physiol Pharmacol; 2018 Jul; 96(7):647-654. PubMed ID: 29842793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.